Infectious Diseases Institute

Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, May 23, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Inflammation, Tufts University Graduate School of Biomedical Sciences, Therapy, Lupus, Head, Infectious Diseases Institute, Inflammation Research, Multimedia, SLE, Biomarker, Doctor of Philosophy, Harvard Medical School, Exo, Santa Clara University, Patient, Autoimmune disease, TBK1, Biomedical sciences, AGS, Pharmaceutical industry, Sanofi, Immunology, Biology

Dr Joseph will be responsible for leading biology, translational and pre-clinical work for Exo’s programs.

Key Points: 
  • Dr Joseph will be responsible for leading biology, translational and pre-clinical work for Exo’s programs.
  • This press release features multimedia.
  • She also previously served as Head of Translational research at Kiniksa Pharmaceuticals, where she was responsible for the design and implementation of translational research strategy for the company.
  • Exo intends to declare a development candidate in their lead program later this year and enter the clinic within the next two years.

Mats Danielsson receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000.

Retrieved on: 
Thursday, December 8, 2022
Rolf Schock Prizes, Danielsson, Physics, Degenerative disease, Swedish Medical Society, Science, KI, KTH Royal Institute of Technology, Diagnosis, Swedish Foundation for Strategic Research, Karolinska Institute, Department of Engineering Science, University of Oxford, IVA, Cancer, Royal Swedish Academy of Sciences, Research, Infectious Diseases Institute, Nobel Committee, CERN, Silicon, Swedish Research Council, Royal Academy of Arts, Value Partners (asset management), Erna, Education, Research Foundation – Flanders (FWO), Organization, Electronics, SEK, Risk, Pharmaceutical industry, Medical imaging, EU

STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.

Key Points: 
  • STOCKHOLM, Dec. 8, 2022 /PRNewswire/ -- The Hans Wigzell's Research Foundation awards its annual scientific prize, to Professor Mats Danielsson at the KTH Royal Institute of Technology in Stockholm.
  • Professor Mats Danielsson receives the prize of SEK 925,000 for his research around medical imaging technology, a technology that can enable earlier diagnosis of cancer and cardiovascular diseases.
  • Mats Danielsson leads a research group at KTH Royal Institute of Technology in physics of medical imaging.
  • Mats Danielsson has a background as a particle physicist and wrote his dissertation on a thesis based on research at CERN.

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Retrieved on: 
Wednesday, October 19, 2022
RNA transfection, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Private Securities Litigation Reform Act, Company, JN-International Medical Corporation, LNC, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Boulware, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, Form 10-K, Washington Convention Center, Risk, Sale, SEC, Society, Patient, Infection, Partnership, Forward-looking statement, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.

Key Points: 
  • Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.
  • IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
RNA transfection, Adult, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, University of Minnesota, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Amphotericin B, Private Securities Litigation Reform Act, Company, LNC, Mycosis, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, ID, Form 10-K, Washington Convention Center, Risk, Physician, Sale, Harbor–UCLA Medical Center, SEC, ABC, Patient, Infection, Partnership, Society, Abstract (summary), Forward-looking statement, Mucormycosis, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person at the Walter E. Washington Convention Center, in Washington DC from October 19-23, 2022.

Key Points: 
  • The data from these three presentations provide a deeper understanding of MAT2203s safety profile and impressive efficacy against two of the deadliest invasive fungal infections in cryptococcal meningitis and mucormycosis, said Theresa Matkovits, Ph.D., Chief Development Officer of Matinas BioPharma .
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • The Company is focused on developing an internal and external pipeline of drugs candidates based on the LNC platform.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Gonçalo Castelo-Branco receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000

Retrieved on: 
Friday, September 16, 2022
Swedish Foundation for Strategic Research, Royal Swedish Academy of Sciences, Infectious Diseases Institute, Multiple sclerosis, Karolinska Institute, National Society for Medical Research, Department, University, Brain, Eric, SSMF, Chemistry (relationship), Anglo-Swedish Society, MS, Chromatin, SEK, Value Partners (asset management), Cell, Medical research, European Research Council, B cell, Doctor of Philosophy, Degenerative disease, Rolf Schock Prizes, UCL Faculty of Engineering Sciences, Science, IVA, Research, DNA, Biophysics, Neuron, KI, Nobel Committee, Education, Disease, Epigenomics, Pharmaceutical industry, Medicine

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).

Key Points: 
  • STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).
  • Professor Gonalo Castelo-Branco receives the prize of SEK 925,000 for his important research around oligodendrocytes a cell type which plays important roles in relation to how the human brain develops and functions.
  • In his research, Professor Castelo-Branco has shown how a cell's DNA can be controlled to develop into an oligodendrocyte.
  • His research has already helped build a better understanding of multiple sclerosis (MS) and can hopefully also lead to improved therapy against this difficult disease.

The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in sub-Saharan Africa

Retrieved on: 
Tuesday, August 2, 2022
Sabin, Rockefeller Foundation, COVID-19, Human, INGO, Twitter, Makerere University, Vaccine hesitancy, Research, Partnership, Solution, Personal protective equipment, Amref Health Africa, Amref International University, Sabin Vaccine Institute, Infectious Diseases Institute, USD, List of health departments and ministries, International, Organization, Leadership, Policy, Ministry, Technology, Ecosystem, Science, Immunization, VAN, Global Health Security Initiative, Vaccination, Program, Communication, HIV, IDI, GVI, Vaccine, Pharmaceutical industry, Medical device, Wakiso Town, Health

NAIROBI, Kenya, August 2, 2022 /PRNewswire/ -- The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies. Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

Key Points: 
  • "The Vaccination Action Network's community-based approach brings together our counterparts from across the region and country.
  • This collaboration is the key to finding and implementing the right vaccination approach," said Dr. Diana Atwine, Permanent Secretary, Ministry of Health, Uganda.
  • While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses.
  • "The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership," said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office.

Tampa General Hospital's Steven Chew Named to Modern Healthcare's Top Emerging Leaders List

Retrieved on: 
Tuesday, March 29, 2022
People, GE Healthcare, Family, Lead, University, Tampa General Hospital, Culture, Adult, Health care, Research, Modern Healthcare, Hospital, Rutgers University, CEO, Public health, Neuroscience, Infectious Diseases Institute, Senior administration official, State, Hospitality Review, GEDI, Education, Home, Artificial intelligence, Institute, Materials management, Job satisfaction, Fast Track, EVP, Investment, Growth, Institute of Nuclear Materials Management, PDI, Operations management, Health, Trauma, U.S. News & World Report, TGH, Patient, Forbes, Organization, Leadership, Intensive care unit, News, Lead service line, Learning, Woman, COVID-19, Physician, Ron Chew, Medicine, Management, Orthopedic surgery, Chewing

TAMPA, Fla., March 29, 2022 /PRNewswire/ -- Steven Chew, vice president, Service Lines at Tampa General Hospital (TGH) is among Modern Healthcare's 2022 class of Top Emerging Leaders. Modern Healthcare, the leader in health care business news, research, and data, annually honors emerging leaders all age 40 or under, who have made significant contributions in the areas of innovation and financial, operational, and clinical excellence early in their careers. Chew has spent most of his career at TGH developing his leadership and management skills, seizing new professional opportunities afforded him by the organization, and taking advantage of the organization's investment in him to enhance his capacity and career trajectory. This national award recognizes his achievements at TGH.

Key Points: 
  • TAMPA, Fla., March 29, 2022 /PRNewswire/ --Steven Chew, vice president, Service Lines at Tampa General Hospital (TGH)is among Modern Healthcare's 2022 class of Top Emerging Leaders.
  • Chew continued to develop his management and leadership skills and moved into the role of Senior Administrator of the Neurosciences, Orthopedics and Infectious Diseases Institutes.
  • Tampa General leads the regional market with educational benefits supporting team members to provide world-class patient care.
  • Tampa General Hospital's footprint includes 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Brandon Healthplex, TGH Virtual Health, and 19 outpatient Radiology Centers.

Children’s National Hospital Launches $500 Million Campaign to Transform Pediatric Health

Retrieved on: 
Wednesday, October 27, 2021
Research, Brain, Mother, Volunteering, U.S. News & World Report, Harwell Science and Innovation Campus, Human, Family, Child, Patient, Infectious Diseases Institute, Lists of diseases, Autism, Cancer, Bed, Nursing, Doctor of Philosophy, Precision medicine, No, Hospital, Movement disorders, CEO, Environment, Health, News, Colorectal surgery, Epilepsy, Burns, GLOBE, Treatment, Anglo-French Wars, Medicine, Medical imaging

WASHINGTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a campaign to raise $500 million by 2023 to deliver lifesaving care and research for kids.

Key Points: 
  • WASHINGTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a campaign to raise $500 million by 2023 to deliver lifesaving care and research for kids.
  • Childrens National Hospital, based in Washington, D.C., celebrates150yearsof pediatric care, research and commitment to community.
  • In 2021, the Childrens National Research & Innovation Campus opened, the first in the nation dedicated to pediatric research.
  • Childrens National is home to the Childrens National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation .